

**Supplementary Table 1.** Descriptive characteristics of the 1033 acromegalic patients with available follow-up data.

	<b>Overall</b>	<b>Study cohort</b>	<b>P value</b>
N. of centers	18	11	
N. of patients reported/total, n (%)	1033/1178 (88)	811/842 (96)	
Gender, M (%)	427 (41.3)	337 (41.6)	0.3
Age at diagnosis, mean $\pm$ SD, y	44.7 $\pm$ 13	44.7 $\pm$ 13	0.9
Age at death or at last visit, mean $\pm$ SD, y	60.8 (13.7)	60.2 $\pm$ 13.7	0.9
Follow- up, mean $\pm$ SD, y	15.5 (8.3)	15.4 $\pm$ 8.3	0.8
Smoking habit, n (%)	134 (20.7)	117 (22.3)	0.5
Obesity, n (%)	185 (26.9)	156 (28.8)	0.5
Hypertension, n (%)	492 (54.5)	391 (53.6)	0.7
Diabetes, n (%)	250 (26.9)	208 (28)	0.6
GH deficiency, n (%)	70 (7.8)	59 (8.4)	0.8
Central hypothyroidism, n (%)	284 (30.5)	222 (30)	0.85
Central hypoadrenalism, n (%)	188 (20)	157 (21.2)	0.7
Central hypogonadism, n (%)	288 (31.3)	242 (33.6)	0.36
GH at diagnosis, mean $\pm$ SD, $\mu$ g/dL	34.6 (68.8)	34.8 $\pm$ 70	0.95
IGF1 at diagnosis, mean $\pm$ SD, $\mu$ g/dL	755.5 $\pm$ 339.7	760.5 $\pm$ 338	0.72
IGF1 at diagnosis, mean $\pm$ SD, ULN	3.83 $\pm$ 4.1	3.85 $\pm$ 4.2	0.83
Number of deaths, n (%)	193 (18.7)	153 (18.9)	0.9

GH, Growth Hormone; IGF1, Insulin Growth Factor I; SD, standard deviation; ULN, upper limits of normal.

**Supplementary Table 2.** Multivariate model for independent predictors of mortality (n = 564).

<b>Variables</b>	<b>HR</b>	<b>95% CI</b>	<b>P value</b>
Gender	1.01	0.65-1.57	0.97
Age	3.98	2.65-5.99	<b>&lt; 0.001</b>
IGF1 above ULN at last follow-up	2.52	1.59-4.01	<b>&lt; 0.001</b>
Therapy			
- Surgical and medical vs multimodal with RT	1.45	0.83-2.51	0.19
- Surgical vs multimodal with RT	1.94	0.90-4.19	0.09
- Medical vs multimodal with RT	1.31	0.68-2.55	0.42
Hypertension	1.13	0.67-1.90	0.64

HR, Hazard Ratio; IGF1, Insulin Growth Factor I; multimodal therapy includes any combination of at least two types of treatment (medical, surgical or radiation, either radiotherapy or radiosurgery); ULN, upper limits of normal.